Compare ANIX & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | TTEC |
|---|---|---|
| Founded | 1982 | 1982 |
| Country | United States | United States |
| Employees | N/A | 69400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 109.0M |
| IPO Year | 2013 | 1996 |
| Metric | ANIX | TTEC |
|---|---|---|
| Price | $3.42 | $2.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 245.1K | ★ 359.9K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 40.80 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $1,509,171,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $2.32 | $1.91 |
| 52 Week High | $5.46 | $3.99 |
| Indicator | ANIX | TTEC |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 60.80 |
| Support Level | $2.77 | $2.42 |
| Resistance Level | $3.53 | $2.66 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 20.69 | 79.31 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.